Therefore, understanding the intricate interactions between BDNF, TrkB, Shp2, and caveolin proteins holds significant promise for the development of novel therapeutic strategies to halt or delay disease progression and ultimately improve the clinical management of glaucoma patients. This evidence concerns the gene NTRK2 and glaucoma.